> 2003 Publications
1.
Surrogate end point for prostate cancer-specific mortality
after radical prostatectomy or radiation therapy.
D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen M:
JNCI, 95:1376-83, 2003.
Abstract
| 
PDF
2.
Diagnostic Potential Of Serum Proteomic Patterns In
Prostate Cancer.
Bañez LL, Prasanna P, Sun L, Ali A, Zou Z, Adam B-L,
McLeod DG, Moul JW and Srivastava S:
J. Urol., 170:442-6, 2003.
Abstract
|
PDF
3.
Factors associated with blood loss during radical prostatectomy
for localized prostate cancer in the prostate-specific antigen
(PSA)-era: an overview of the Department of Defense (DOD) Center
for Prostate Disease Research (CPDR) national database.
Moul JW, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton
W, Kusuda L, Chung A, Soderdahl D, Donahue T.
Urol Oncol. 21:447-55,2003.
Abstract
|
PDF
4. PMEPA1, an androgen-regulated NEDD4-binding protein,
exhibits cell growth inhibitory function and decreased expression
during prostate cancer progression.
Xu LL, Shi Y, Petrovics G, Sun C, Makarem M, Zhang W, Sesterhenn
IA, McLeod DG, Sun L, Moul JW, Srivastava S.
Cancer Res. 63: 4299-304, 2003.
Abstract
|
PDF
5. Using the percentage of biopsy cores positive for cancer,
pre-treatment PSA, and highest biopsy Gleason sum to predict pathologic
stage after radical prostatectomy: The Center for Prostate Disease
Research nomograms.
Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, Herring
J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Moul JW:
Urology, 61:589-95,2003.
PDF
6.
Predictors of extracapsular extension and positive margins
in African-American and Caucasian men.
Paquette EL, Connelly RR, Sun L, Paquette LR, Moul JW:
Urologic Oncology, 21:33-8, 2003.
Abstract
|
PDF
7.
Pretreatment total testosterone level predicts pathologic
stage in radical prostatectomy patients with localized prostate
cancer.
Massengill JC, Sun, Moul JW, Wu H, McLeod DG, Amling C, Lance
R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue
T:
J Urol, 169:1670-5, 2003.
Abstract
8.
Effect of age on biochemical disease-free outcome in patients
with T1-T3 prostate cancer treated with definitive radiotherapy
in an equal-access health care system: a radiation oncology report
of the Department of Defense Center for Prostate Disease Research.
Johnstone PA, Riffenburgh RH, Moul JW, Sun L, Wu H, McLeod DG,
Kane CJ, Martin DD, Kusuda L, Lance R, Douglas R, Donahue T, Beat
MG, Foley J, Chung A, Soderdahl D, Do J, Amling CL:
Int J Radiat Oncol Biol Phys. 55:964-9, 2003.
Abstract
|
PDF
